Systematic Survey of the Role of IGF in the Link Between Diabetes and Cancer by Devanathan, Nirupama & Kimble-Hill, Ann C.
Systematic Survey of the Role of IGF in the Link Between 
Diabetes and Cancer
Nirupama Devanathan and Dr. Ann C. Kimble-Hill [Faculty Mentor]
Indiana University School of Medicine
Abstract
Epidemiological studies have proposed a link between type II diabetes and cancer via the IGF/
insulin signaling pathway, which includes insulin-like peptides (IGF1, IGF2, and insulin), insulin 
receptors (IR-A, IR-B, IGF1R, and hybrids), and insulin substrate proteins (IRS1–6). In this study, 
up- and down-regulation of various components in the IGF/insulin signaling pathway are 
compared to clinical outcomes for cancer patients; the components include diagnosis age, overall 
survival, tumor invasion and vascularization, and body mass index. It was found that the up-
regulation of insulin growth Factor (IGF)/insulin components was associated with overall survival 
and tumor invasion and vascularization, while the down-regulation of equivalent components was 
not associated with clinical outcomes assessed in this study. Particularly, the up-regulation of 
DOK5, IGF2, and IRS2 in colorectal cancer and IGF1R in liver cancer is associated with 
significantly decreased overall survival. Functional aberrations in either of the two proteins in co-
expression pairs were identified for each cancer and correlated with overall survival and diagnosis 
age. Specific biomarkers proposed in this study will be further analyzed to fine-tune consistent 
associations that can be translated to reliable prognostic standards for the roles of IGF/insulin 
signaling pathway modulations that promote cancer.
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INTRODUCTION
Type II diabetes mellitus (T2DM) and cancer of the liver, pancreas, endometrium, colorectal, 
breast, and bladder share a number of epidemiological trends (Arcidiacono et al., 2012a; 
Giovannucci et al., 2010; Vigneri, Frasca, Sciacca, Pandini, & Vigneri, 2009). Traditionally 
associated with industrialized nations, cancer and T2DM are growing epidemics in lower- 
and middle-income nations. By 2025, 20 million new cancer cases are predicted, with the 
greatest incidence in the developing world (Ferlay et al., 2015). Of even greater concern, the 
global population of people living with T2DM continues to soar. By 2030, 440 million 
people are expected to develop T2DM, with the greatest prevalence occurring in the densely 
populated nations of India, China, and Bangladesh (Chen, Magliano, & Zimmet, 2011).
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Apart from documenting this demographic shift—a pronounced increase in cancer and 
T2DM in less developed nations— epidemiological studies have also proposed T2DM as a 
risk factor to cancer development, implicating shared molecular connections (Arcidiacono et 
al., 2012b; Vigneri et al., 2009). Hyperinsulinemia, an early onset indicator for T2DM 
prognosis, disrupts the insulin growth factor (IGF)/insulin signaling pathway, which, in turn, 
perturbs key signaling pathways that enable cancer cell viability (Arcidiacono et al., 2012a; 
Bowers, Rossi, O’Flanagan, deGraffenried, & Hursting, 2015; Djiogue et al., 2013). 
Furthermore, T2DM hyperglycemic conditions favor cancer’s tendency to metabolize via the 
highly inefficient process of glycolysis—a phenomenon dubbed as the Warburg Effect—by 
providing an extreme surplus in blood glucose (Orgel & Mittelman, 2013).
Consequently, it has been proposed that the IGF/insulin signaling pathway serves as another 
molecular link between T2DM and cancer (Djiogue et al., 2013).
Insulin/IGF Signaling Pathway Proteins Identified and Their Roles
There are three areas of IGF/insulin signaling that may drive this relationship: receptor 
activators such as insulin and IGF; insulin receptor (INSR), insulin growth factor receptor 
(IGFR), and their heterodimers; and the ligands insulin receptor substrate (IRS), IGF 
binding protein (IGFBP), and docking protein (DOK). Insulin and IGF are classified as 
insulin-like peptides which are crucial in the regulation of energy metabolism (Bowers et al., 
2015; Djiogue et al., 2013). Insulin is produced exclusively in the pancreas via beta cells in 
the islets in response to sensing glucose in the blood stream. Insulin plays an essential role in 
the progression of IGF/insulin signaling, as it activates both isoforms of INSR (IR-A and IR-
B). The expression of IR-A is primarily found in metabolic tissues, including the liver 
(Bowers et al., 2015). In the insulin/IGF system, IR-B is insulin-specific and is exclusively 
involved with glucose homeostasis (Djiogue et al., 2013).
IGF is primarily produced in the liver but also generated locally by tumor cells. Growth 
hormone stimulates IGF production in the liver, but IGF can also be produced by cancer 
cells themselves, thereby generating a microenvironment suitable for maintaining cellular 
function in dense tumors where cells face a reduction in insulin stimulation. IGF1 has been 
known to stimulate INSR signaling, as IR-B has been shown to form heterodimers with IGF 
(Bowers et al., 2015). IGF2 is also able to activate IR-A and is found in all adult tissue types 
(Djiogue et al., 2013). Additionally, IGFIR heterodimers have been reported to be found in 
cancerous cells (Djiogue et al., 2013). These receptors typically auto-phosphorylate at the 
beta-subunit tyrosine kinase domains (Cohen & LeRoith, 2012); then, the receptors are able 
to activate INSR.
IGFBP regulates the relative bioavailability of IGF (Baxter, 2014), as hyperinsulinemia 
increases IGF1 bioavailability through the suppression of IGFBP synthesis, promotion of 
oxidative stress, increases in pro-inflammatory cytokines, and promotion of growth hormone 
receptor in the liver, which allows for greater IGF1 synthesis (Arcidiacono et al., 2012b; 
Bowers et al., 2015).
While previous studies have attempted to correlate the different serum levels associated with 
components of IGF/insulin signaling, factors like variable bioavailability have rendered such 
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measures to be less useful (Cohen & LeRoith, 2012). In this study, cancerspecific DNA, 
mRNA, and protein expression data from patients that have liver, pancreatic, uterine, and 
colorectal cancer were obtained from the cBIO Database Portal datasets. Next, genomic and 
proteomic expression changes to components of the IGF/insulin signaling pathway were 
related to risk factors and clinical outcomes for cancer patients. Importantly, this study 
presents associations between clinical outcomes, up- and down-regulated components of 
IGF/insulin signaling, and candidate pro-cancer biomarkers for future investigation.
METHODOLOGY
All data in this study were collected using the cBIO Database Portal, particularly depending 
on The Cancer Genome Atlas (TCGA) provisional studies, as of October 15th, 2017 
(Cerami et al., 2012; Gao et al., 2013). We obtained DNA mutation, mRNA expression, and 
protein expression level data for the following tumor types previously reported to have 
epidemiologically significant association with type II diabetes: liver, uterine, pancreatic, and 
colorectal (Arcidiacono et al., 2012b). Table 1 lists the number of patient samples for each 
tumor type, along with the samples related to changes in IGF/insulin signaling in this 
analysis.
Data Collection and Processing
We used data available from TCGA to analyze up- and down-regulation of IGF/insulin 
signaling protein activity (e.g., IGF1, IGF2, INS, IRS1, IRS2, IRS4, DOK4, DOK5, IGF1R, 
INSR, IGFBP3), defined as −2.5 ≤ Z ≤ 2.5 for both mRNA and protein levels, in the 
previously listed cancers. In addition to explicit over- and under-expression data, up- and 
down-regulation was deduced using mutation information (amplification, function 
depression mutation, or deletion of protein). Function depression mutations were defined as 
those reported to lead to a loss of function (nonsense mutations or frameshift mutations) or 
missense mutations predicted as possibly or probably damaging to function (Gao et al., 
2013). In turn, OncoPrint visualization was used to relate each mutation or annotation to the 
following clinical factors: diagnosis age, overall survival months, overall survival status, 
patient height, patient weight, and vascular invasion. The body mass index (BMI), a 
biometric to track obesity, was calculated for available data sets that contained patient height 
and weight using the following formula: BMI = mass / height2.
Statistical Analysis
Each instance of mutation or annotation was categorized as either up- or down-regulated, 
based on the criteria mentioned above. A two-tailed t-test was conducted to compare over- 
and under-expression for each component of IGF/insulin signaling with the previously 
mentioned clinical factors. Of particular importance, survival rates— statistically determined 
to be significantly associated with the up-regulation of IGF1R, IGF2, IRS2, and DOK5—
were analyzed through measures of central tendency, culminating with corresponding box-
and-whisker plots. Box-and-whisker plots systematically divide the spread of data into 
quartiles, which are essential in developing a precise sense of survivability associated with 
significant changes in the expression of IGF/insulin signaling components.
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Apart from the analysis of up- and down-regulation of IGF/insulin signaling components, 
this study also examined pairs of co-occurring mutations within the system. Internal 
algorithms associated with the cBio Portal were applied to discover the statistically 
significant co-occurrences (p < 0.05). The pairs consistently found across multiple cancer 
types were then proposed as candidate biomarkers to indicate the possible presence of 
cancer or the start of cancer formation in aberrant IGF/insulin conditions, such as 
hyperinsulinemia. A two-tailed t-test was then conducted to analyze possible relationships 
between the 1) simultaneous up-regulation, 2) simultaneous down-regulation, or 3) the up-
regulation/down-regulation of the functional aberrancies in each co-occurrence pair and the 
clinical factors of overall survival and diagnosis age.
RESULTS
Associations that Drive Liver Cancer Patient Outcomes
As shown by the OncoPrint view diagram in Figure 1, less than 10% of mutations within the 
sample set were associated with IGF/insulin signaling, representing a small subset of the 
total cancer cases. Within this subset, pronounced patterns of amplification and mRNA up-
regulation were observed, while deep deletion and missense mutations seemed to occur only 
a few times. In general, the highest number of changes was found to affect DOK5, which 
represented 5% of total samples. The remaining changes, in descending order of percent of 
total samples computed by the cBIO Portal, included: IGF1R (4%), INSR (4%), IRS1 (4%), 
IRS4 (4%), IGF2 (2.4%), DOK4 (2.2%), IRS2 (2.2%), INS (2%), IGF1 (1.5%), and IGFBP3 
(1.3%) (Figure 1). IGF1R and IGFBP3 were found to experience simultaneous mutation or 
change in expression (p = 0.045).
After determining the changes in expression or mutations known within the insulin/IGF 
pathway for these tissues, the effect of these changes on clinical outcomes was determined 
(Table 6). Vascular invasion was extremely minimal, with either an absence of invasion or 
micro-invasion reported in nearly all of the samples. Out of the 123 samples in which 
information for vascular invasion was given, macrovascular invasion was reported in 30% of 
samples (Figure 1). The up-regulation of IRS2 and DOK5, both insulin receptor substrates, 
was correlated with absent or reduced vascular invasion. The up-regulation of IGF1R was 
correlated with lowered overall survival and increased BMI but with absent or reduced 
vascular correlation as well. For IGF1R, only 9% of the cases experienced vascularization, 
IRS2 17% of the cases, and DOK5 42% of the cases (Figure 1). While the up-regulation of 
IGF1R does little to induce vascularization and/or tumor invasion, it is possible that the 
perturbation of the substrate proteins negatively impacts the success of tumor metastasis.
Associations that Drive Pancreatic Cancer Patient Outcomes
Pancreatic ductal adenocarcinoma (PDAC) bears little resemblance to the other three cancers 
with regards to co-occurrence patterns. Within the PDAC subset, pronounced patterns of 
amplification and mRNA up-regulation were observed, while deep deletion and missense 
mutations seemed to occur only a few times in this dataset. The OncoPrint view diagram 
(Figure 2) illustrates that less than 10% of mutations within the sample set were associated 
with IGF/insulin signaling, representing a small subset of the total cancer cases. 
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Qualitatively, there was a wide variety of mutation and annotation types represented in this 
subset—including missense mutation, deep deletion, amplification, and mRNA up-
regulation—with no one particular type of perturbation predominating. A similarly wide 
variety of tumor invasion was also observed in the OncoPrint. In general, the highest number 
of changes in pancreatic cancer was found to affect IRS1, which represented 8% of total 
samples. The remaining changes, in descending order of percent of total samples, included: 
IRS2 (6%), IRS4 (6%), IGF1R (5%), DOK4 (4%), DOK5 (4%), IGFBP3 (3%), INSR (3%), 
INS (1.6%), IGF1 (1.6%), and IGF2 (0.5%) (Figure 2).
Associations that Drive Uterine Cancer Patient Outcomes
The OncoPrint view diagram (Figure 3) illustrates that less than 15% of mutations within the 
sample set were associated with IGF/ insulin signaling, representing a small subset of total 
cancer cases. In general, the highest number of changes in uterine cancer was found to affect 
DOK5, which represented 11% of total samples. The remaining changes, in descending 
order of percent of total samples, included: IGF2 (6%), INS (3%), IRS2 (3%), IRS4 (2.9%), 
IGF1R (2.4%), INSR (2.4%), IRS1 (2.7%), IGFBP3 (1.7%), IGF1 (1.1%), and DOK4 
(0.8%) (Figure 3). Vascular invasion was extremely minimal, with either an absence of 
invasion or micro-invasion reported in nearly all of the samples. We found a significant co-
occurrence (p < 0.001) between the ligands IGF2/INS; receptors/substrates INSR/ IRS1, 
INSR/IRS4, and IGF1R/IRS4; and substrates IRS1/IRS4 and IGFBP3/IRS4 (Table 4).
Associations that Drive Colorectal Cancer Patient Outcomes
The colorectal cancer OncoPrint diagram illustrates that less than 15% of mutations within 
the sample set were also associated with IGF/insulin signaling (Figure 4). In general, the 
highest number of changes was found to affect DOK5, which represented 11% of total 
samples. The remaining changes, in descending order of percent of total samples, included: 
IGF2 (6%), IRS2 (3%), INS (3%), IRS4 (2.9%), IRS1 (2.7%), INSR (2.4%), IGF1R (2.4%), 
IGFBP3 (1.7%), IGF1 (1.1%), and DOK4 (0.8%) (Figure 4).
In colorectal cancer, the up-regulation of DOK5 and IRS2 was associated with overall 
survival status, while in liver cancer, up-regulation was associated with increased vascular 
invasion. On the other hand, the up-regulation of different IGF/insulin signaling components 
can lead to similar clinical outcomes; in colorectal cancer, the up-regulation of IGF1R, along 
with its adaptor proteins, is associated with overall survival. Additionally, the up-regulation 
of DOK5, IGF2, and IRS2 was associated with clinical outcomes of decreased average 
months of survival (Table 6). The median survival was approximately 25 months. Without 
the up-regulation of components in IGF/insulin signaling, the median survival was 83 
months (Figure 5).
DISCUSSION
An association between the up-regulation of most components in IGF/insulin signaling and 
overall survival was observed from the two-tailed t-tests. Down-regulation in IGF/insulin 
signaling did not appear to be associated with clinical outcomes. Associations between 
specific components of IGF/insulin signaling and patient outcomes were unable to be 
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obtained for either uterine or pancreatic cancers due to exceedingly small sample sizes (n < 
10). Despite relatively small sample sizes, these components were vigorously analyzed both 
in co-occurrence pairs and individually relative to clinical outcomes. Based on putative 
molecular connections underlying these relationships, we were then able to propose 
indicative mechanisms.
Analysis of Associations that Drive Liver Cancer Patient Outcomes
The up-regulation of IGF1R was correlated to decreased survival. In liver cancer, the up-
regulation of IGF1R was associated with a median overall survival of just over 15 months, 
compared to 49 months for patients with normal IGF/insulin signaling (Figure 6).
We saw expected correlations between known receptor/binding protein pairs IGF1R/IGFBP3 
(Table 2). A two-tailed t-test between patients that had aberrations in either IGF1R or 
IGFBP3 activity demonstrated that there is no statistical difference in the overall diagnosis 
age (p = 0.627), suggesting that up-regulation at either the receptor or binding protein levels 
demonstrates a statistically equivalent impact on the overall diagnosis age. In contrast, a 
statistically significant difference between the up-regulation of these two components in 
terms of overall survival time (p = 0.0255) was observed. When alterations in IGF1R and 
IGFBP3 co-occur, the relative activity within the pair in relation to overall cancer survival is 
shown to be different. The up-regulation of IGF1R has been associated with increased 
proliferation and overall cell survival, and correspondingly, decreased overall survival by 
promoting disease progression. On the other hand, while literature has related the down-
regulation of IGFBP3 to tumor suppressing functionality, the impact of IGFBP3 up-
regulation requires further investigation (Rebhan, Chalifa-Caspi, Prilusky, & Lancet, 1998). 
Aberrancies in binding proteins like IGFBP3, which control the relative bioavailability of 
insulin-like peptide, affect the receptor and receptor substrate proteins, which, in turn, 
participate in crucial segments of cancer-inducing cell signaling.
Analysis of Associations that Drive Pancreatic Cancer Patient Outcomes
Due to the small sample size of patients with changes in expression, we could not determine 
the effects of genomic and/or proteomic changes in IGF/insulin signaling on clinical 
outcomes with confidence. As illustrated in Table 3, DOK4 and INSR was the only IGF/
insulin signaling pair that showed significant co-occurrence in pancreatic cancer. This 
correlation suggests that DOK4 is the most likely candidate to propagate the INSR signal in 
pancreatic cancer; however, it may have no clinical relevance for patient outcomes. These 
results also suggest that pancreatic tumor metabolism does not mirror that of liver tumor 
metabolism.
Analysis of Associations that Drive Uterine Cancer Patient Outcomes
We then assessed whether functional connections remained the same between the co-
occurrence pairs identified in uterine cancer. We performed two-tailed t-tests on patient 
diagnosis age and survival to determine the relationship between having functional 
aberrations in either of the two proteins in the pairs identified.
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Particularly in uterine cancer, the up-regulation of one gene and the down-regulation of the 
other within the co-occurrence pair proved to be significant in several cases. For instance, a 
statistically significant difference was found between the down-regulation of IRS4 and the 
up-regulation of IGF1R in terms of overall survival (p = 0.08) and overall diagnosis age (p = 
0.001), respectively. We found a statistically significant difference in the simultaneous up-
regulation or simultaneous down-regulation of both IRS1 and IGF1R in relation to overall 
survival months (p=0.001). We also found a statistically significant difference in relation to 
overall survival in months for the following pairs: 1) up-regulation of DOK4 and DOK5 (p = 
0.05); 2) down-regulation of DOK4 and DOK5 (p = 0.01); 3) up-regulation of DOK4 and 
down-regulation of DOK5 (p = 0.09); and 4) down-regulation of DOK4 and up-regulation of 
DOK4 (p = 0.02).
On the other hand, no statistically significant difference was noted between the down-
regulation of IRS1 and the up-regulation of IRS4 (p = 0.08) relative to overall patient 
survival. We found no statistical difference in the up-regulation of IGF1 and IRS2 (p = 0.9) 
or when IGF1 is up-regulated and IRS2 is down-regulated (p = 0.1), relative to diagnosis 
age. Similarly, we found no statistically significant difference between IGF1 and IGF1R in 
relation to diagnosis age, either when IGF1 is up-regulated and IGF1R is down-regulated (p 
= 0.8) or when both are simultaneously up-regulated (p = 0.5); in addition, we did not find a 
statistically significant difference between the down-regulation of IRS1 and the up-
regulation of IGF1R, relative to diagnosis age (p = 0.1). We found no statistically significant 
difference between IGF1 and IRS4 in relation to diagnosis age, either when IGF1 is up-
regulated and the IRS4 is down-regulated (p = 0.8) or when both are simultaneously up-
regulated (p = 0.9)
As a result of determining these correlations, we began to hypothesize the role of each 
protein pair in uterine cancer. For instance, IRS1 has been shown to activate 
phosphatidylinositol 3-kinase, while IRS4 is implicated in suppressing IRS2 (Rebhan et al., 
1998). Both substrate proteins, IRS1 and IRS4, act in opposition to one another, possibly 
accounting for the significance shown between the up- and down-regulation within the co-
occurrence pair respectively (Rebhan et al., 1998). Again, as noted earlier, IRS4 is involved 
in the suppression of IRS1 and IRS2. The down-regulation of IRS4—which has a repressor 
function—along with the up-regulation of IGF1R—which will continue the signaling 
cascade downstream to growth pathways like the mitogen-activating protein kinase (MAPK) 
signaling pathway—act together to effectively promote disease progression while 
contributing to lower diagnosis age and overall survival respectively (Rebhan et al., 1998). 
As a direct adaptor protein of IGF1R with downstream activating functionality, the finding 
of statistical significance between simultaneous up- or down-regulation of IRS1 was 
surprising and requires future investigation to deduce the exact nature of this co-occurrence. 
As noted earlier, a statistically significant difference was found between DOK4 and DOK5 
adaptor proteins that experienced either 1) simultaneous up-regulation; 2) simultaneous 
down-regulation; or 3) up-regulation of one member of the co-occurrence pair and down-
regulation of the other. These two adaptor proteins both play a role in activating MAPK 
signaling, and as such, could represent a functional redundancy (Rebhan et al., 1998). The 
up-regulation of IGF1, as the ligand protein, remains consistent between the two co-
occurrence pairs, suggesting its impact on encouraging tumor growth, regardless of the up- 
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or down-regulation of IGF1R. The relationship between IGF1 and IRS4 also fits this pattern 
in which there is a statistically significant difference between the up-regulation of IGF1 and 
both the up- and down-regulation of IRS4. Again, this observation underscores the impact of 
up-regulation at the ligand level, prompted by diabetic conditions, in promoting malignancy.
We found no difference in the diagnosis age or time of survival when either IGF1R or IRS4 
is down-regulated. However, there is a slight difference between the diagnosis age when 
IGF1R is up-regulated compared to when IRS4 is down-regulated (~71 vs ~62 years old 
respectively, p = 0.08). For the substrates IRS1 and IRS4, there was no significant difference 
in diagnosis age when either was up-regulated or down-regulated, although there was a 
significant difference in survival time when the activity of the pairs was reciprocal to one 
another. Down-regulating IRS4 appears to lengthen survival time by ~25 months (p = 0.08). 
The opposing effect was seen in the other direction; however, the small sample size 
decreased our ability to confidently quantify this effect. We were unable to obtain large 
enough patient sample sizes to determine the correlations of the other co-occurrence 
partners. Based on the information gathered, we hypothesize that 1) IRS1 and IRS4 work in 
tandem, leading to the same clinical outcome of having a disease onset at an earlier age, but 
decreasing either lengthens the survival rate; and 2) increased IGF1R activity may reduce 
the effects of losing IRS4 activity, leading to onset of the disease at a later age.
Analysis of Associations that Drive Colorectal Cancer Patient Outcomes
We then looked at the co-occurrence of protein function (Table 5). We again saw 
connections between activators IGF/INS and substrates IRS/DOK. The dataset also 
demonstrated co-occurrences between the activator/receptor pair IGF/INSR and receptor/
substrate pair INSR/DOK. Specifically, the statistically significant relationships included: 
ligand relationships between IGF2/INS (p < 0.001); receptor relationships between IGF1R/
INSR (p=0.05); receptor/substrate relationships between INSR/DOK4 (p = 0.005) and 
INSR/IGFBP3 (p = 0.03); ligand/substrate relationships between IGF2/IRS4 (p = 0.02); and 
substrate relationships between DOK5/IRS2 (p = 0.02) and IGFBP3/IRS4 (p = 0.04). Based 
on these relationships, we looked at the data set more closely to determine the functional 
connections between these pairs.
We then performed two-tailed t-tests on patient diagnosis age and survival to determine the 
relationship between having functional aberrations in either of the two proteins in the pairs 
identified. We found no statistically significant difference between the up-regulation of IGF2 
or INS in the overall diagnosis age (p = 0.6) or overall survival (p = 0.7). Similarly, the up-
regulation of IGF2 and the down-regulation of INS are statistically equivalent in both overall 
diagnosis age (p = 1) but not in overall survival (p = 0.07). We also saw no statistically 
significant difference between the up-regulation of IGF2 and down-regulation of DOK5 with 
regards to diagnosis age (p = 1). We did, however, find a statistically significant difference 
between the up-regulation of IRS2 and DOK5 with regards to diagnosis age and overall 
survival (p < 0.001). Based on the sample size, we were unable to determine correlations 
between INSR/DOK4, INSR/ IGFBP3, IGFBP3/IRS4, and INSR/IGF1R.
As a result of determining these correlations, we began to hypothesize the role of each 
protein pair’s activity in colorectal cancer. As ligands of IGF/insulin signaling, IGF2 and 
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INS share several receptor sites, achieved through hybridization and the versatility of the 
individual receptors. The statistical equivalence, therefore, is not entirely surprising (Baxter, 
2014) and suggests an increased ability of these cells to respond to hyperglycemic 
conditions. The correlations then point to a role for downstream effects of increased receptor 
signaling in these conditions. DOK5, as an adaptor protein, is critical to signal transduction, 
especially in its interaction with the tyrosine kinase insulin receptors. The down-regulation 
of DOK5 would preclude its ability to regulate the downstream MAPK signaling pathway, 
while the up-regulation of IGF2 would also initiate downstream cell signaling without 
regulation. The relative equivalence of DOK5 as an adaptor and IGF2 as a ligand 
underscores the importance of the shared insulin receptor at the center of the pathway 
(Dunant, Wisniewski, Strife, Clarkson, & Resh, 2000; Rebhan et al., 1998). Both IRS2 and 
DOK5 are adaptor proteins and, as previously mentioned, are critical to successful signal 
transduction. Despite the overall similarity in function, the two proteins diverge in specific 
interactions. For instance, IRS2 interacts with the RET proto-oncogene, which is associated 
with several endocrine tumors, but DOK5 does not interact with p21, an important player in 
cell growth and mitogenic functionality, requiring further studies to better elucidate its role 
in promoting cancer progression (Dunant et al., 2000; Rebhan et al., 1998).
CONCLUSIONS
We conducted this study of using clinical observations and patient statistics to further our 
understanding of the correlation between T2DM and cancer of four specific tissues (liver, 
pancreas, uterine, and colon). Based on our statistical analyses, we found specific 
correlations between functional activity of proteins that initiate glucose metabolism and 
clinical outcomes specific to cancer type. This study suggests that the up-regulation of 
components in IGF/insulin signaling is associated with significantly decreased survivability, 
while, in contrast, down-regulation does not appear to be associated with cancer-related 
clinical outcomes. While different tissues shared co-occurrence pairs, evidence from this 
study proposes distinct patterns of functional aberrations as well as co-occurring protein 
pairs that could serve as biomarkers signaling potential hyperinsulinemia-induced 
tumorigenesis and clinical outcomes.
As such, we propose that INSR/DOK4(5), shared by uterine, pancreatic, and colorectal 
cancers, and IGF1R/IGFBP3, shared by uterine and liver cancers, are general biomarkers of 
diabetes-based cancer. Evidence demonstrates that uterine cancer can be uniquely 
characterized by the co-occurrences of INS/IGF2, IRS1/IRS4, INSR/ IRS1, IGFBP3/IRS4, 
IGF1R/IRS4, IGFBP3/IRS1, IGF1R/IGFBP3, IGF1R/INSR, IGFBP3/INSR, IGF1/IRS1, 
IGF1/IRS1, IGF1/IGF1R, IGF1R/IRS1, IGF1R/IRS1, IGF1/INS, DOK4/DOK5, DOK5/
IGF2, INSR/DOK5, IGF1/IRS4, and IGF1/INSR. Colorectal cancer can be characterized by 
the co-occurrence of IGF2/INS, IRS4/IGF2, DOK5/ IRS2, IGFBP3/INSR, IGFBP3/IRS4, 
and IGF1R/INSR. Subsequent studies will analyze these putative genomic biomarkers to 
develop reliable prognostic standards for cancers promoted by T2DM.
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APPENDIX
Table 1.
Total Number of Samples of Each Tumor Type
Cancer Type Number of Samples Number of Samples with Changes Related to IGF/Insulin Signaling
Pancreatic 185 64
Uterine 113 547
Liver 440 166
Colorectal 629 177
Table 2.
Liver Cancer: Significant Co-Occurring Mutation Pairs
Gene A Gene B
No. of Patients
Log Odds Ratio p-Value Tendency
Neither A Not B B Not A Both
IGF1R IGFBP3 394 29 15 4 1.287 0.047 Co-occurrence
Table 3.
Pancreatic Ductal Adenocarcinoma: Significant Co-Occurring Mutation Pairs
Gene A Gene B
No. of Patients
Log Odds Ratio p-Value Tendency
Neither A Not B B Not A Both
INSR DOK4 174 4 6 2 2.674 0.022 C-occurrence
Table 4.
Uterine Cancer: Significant Co-Occurring Mutation Pairs
Gene A Gene B
No. of Patients
Log Odds Ratio p-Value Tendency
Neither A Not B B Not A Both
INS IGF2 533 2 4 9 >3 <0.001 Co-occurrence
IRS1 IRS4 513 13 13 8 >3 <0.001 Co-occurrence
INSR IRS1 510 17 13 7 2.708 <0.001 Co-occurrence
IGFBP3 IRS4 523 3 18 4 >3 <0.001 Co-occurrence
IGF1R IRS4 509 17 16 6 2.418 <0.001 Co-occurrence
INSR IRS4 508 18 16 6 2.359 <0.001 Co-occurrence
IGFBP3 IRS1 523 4 18 3 >3 0.002 Co-occurrence
IGF1R IGFBP3 521 20 4 3 2.972 0.002 Co-occurrence
IGF1R INSR 506 18 19 5 2.001 0.002 Co-occurrence
IGFBP3 INSR 520 4 21 3 2.922 0.002 Co-occurrence
IGF1 IRS1 522 5 18 3 2.856 0.002 Co-occurrence
IGF1 IGF1R 520 5 20 3 2.747 0.003 Co-occurrence
IGF1R IRS1 508 19 17 4 1.839 0.009 Co-occurrence
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Gene A Gene B
No. of Patients
Log Odds Ratio p-Value Tendency
Neither A Not B B Not A Both
IGF1 INS 531 6 9 2 2.979 0.01 Co-occurrence
DOK4 D0K5 513 9 22 3 2.053 0.013 Co-occurrence
DOK5 IGF2 513 22 10 3 1.945 0.018 Co-occurrence
INSR DOK5 503 20 21 4 1.567 0.019 Co-occurrence
IGF1 IRS4 520 6 20 2 2.159 0.037 Co-occurrence
IGF1 INSR 518 6 22 2 2.06 0.044 Co-occurrence
Table 5.
Colorectal Cancer: Significant Co-Occurring Mutation Pairs
Gene A Gene B
No. of Patients
Log Odds Ratio p-Value Tendency
Neither A Not B B Not A Both
IGF2 INS 588 26 6 13 >3 <0.001 Co-occurrence
INSR DOK4 615 13 3 2 >3 0.005 Co-occurrence
IRS4 IGF2 580 13 35 4 1.555 0.02 Co-occurrence
DOK5 IRS2 550 61 16 6 1.218 0.021 Co-occurrence
IGFBP3 INSR 609 9 13 2 2.343 0.025 Co-occurrence
IGFBP3 IRS4 606 9 16 2 2.13 0.036 Co-occurrence
IGF1R INSR 605 13 13 2 1.968 0.046 Co-occurrence
Table 6.
Significant Clinical Outcomes Associated with the Up-Regulation of IGF/Insulin with Two-
Tailed T-Test Values
Cancer IGF/insulin Signaling Component Sample # Clinical Effect p- value
Liver
↑IRS2 n=21
Vascular Invasion
<0.0001
BMI
↑D0K5 n=12 Vascular Invasion <0.0001
↑TIGF1R n=13
Overall Survival
<0.0001Vascular Invasion
BMI
Colorectal
↑DOK5 n =46 Overall Survival <0.0001
↑TIRS2 n=13 Overall Survival <0.0001
↑TIGF2 n=17 Overall Survival <0.005
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Figure 1. OncoPrint View of Liver Cancer.
The mutations and annotations for the respective samples in liver cancer are presented, along 
with corresponding clinical outcomes: diagnosis age, overall survival in months, overall 
survival status, patient height, patient weight, and vascular invasion.
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Figure 2. OncoPrint View of Pancreatic Cancer.
The mutations and annotations for the respective samples in pancreatic cancer are presented, 
along with corresponding clinical outcomes: diagnosis age, overall survival in months, 
overall survival status, patient height, patient weight, and tumor invasion percent.
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Figure 3. OncoPrint View of Uterine Cancer.
The mutations and annotations for the respective samples in uterine cancer are presented, 
along with corresponding clinical outcomes: diagnosis age, overall survival in months, 
overall survival status, and personal medical history of T2DM.
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Figure 4. OncoPrint View of Colorectal Cancer.
The mutations and annotations for the respective samples in colorectal cancer are presented, 
along with corresponding clinical outcomes: diagnosis age, overall survival in months, 
overall survival status, patient height, patient weight, and vascular invasion. Note that patient 
height and weight data are largely unavailable in this study.
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Figure 5. Survival (Months) for IGF2, IRS2, and DOK5 in Colorectal Cancer.
Three box-and-whisker plots are given to compare the spread of patient survival data in 
colorectal cancer and particularly emphasize the low median survival for each observed 
component. Samples with the up-regulation of DOK5 exhibit the greatest range of survival 
outcomes.
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Figure 6. Survival (Months) for IGF1R in Liver Cancer.
The box-and-whisker plot is given to compare the spread of patient survival data in liver 
cancer. The medians are represented as the center of the plot.
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